PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 8742730

AVS software for visualization in molecular microscopy.

B Sheehan·S D Fuller·M E Pique·M Yeager
View original source ↗Export metadata ↓

Abstract

AVS (Application Visualization System) is commercially available software for analyzing and viewing data. AVS is primarily used in the physical sciences and engineering, and here we describe the application of AVS for examining three-dimensional density maps generated by electron microscopy and image processing. For this purpose, AVS can be applied with relative ease, even though the software is indeed quite sophisticated. The primary advantage is that visualization applications can be generated by combining software components, called modules, into executable flow networks. Simple networks are described for generating ribbon diagrams of macromolecules, surface-shaded views, and contour maps. Easy to use dials, bar sliders, and buttons provide tremendous versatility for real-time manipulation of isosurface values, depth cueing, view orientation, size, and animation. In addition, AVS supplies a framework for building new modules in C or FORTRAN. Modules for excavation and cropping provide tools that are particularly useful for extracting segments of a map and for examining maps of supramolecular complexes such as viruses. We describe a number of modules we have designed for analysis of three-dimensional data sets, as well as modules for importing image data from other software packages into AVS. We also describe xformat, a stand-alone file conversion utility designed to allow import of a variety of image and map file formats into AVS.

Explore related subjects

CapsidCapsid ProteinsFreezingMicroscopy, ElectronModels, StructuralRotavirusSoftwareJournal ArticleResearch Support, Non-U.S. Gov'tResearch Support, U.S. Gov't, P.H.S.

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

B Sheehan, S D Fuller, M E Pique, M Yeager. AVS software for visualization in molecular microscopy.. https://doi.org/10.1006/jsbi.1996.0017

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2017

A directed evolution approach to select for novel Adeno-associated virus capsids on an HIV-1 producer T cell line.

A directed evolution approach was used to select for Adeno-associated virus (AAV) capsids that would exhibit more tropism toward an HIV-1 producer T cell line with the long-term goal of developing improved gene transfer vectors. A library of AAV variants was used to infect H9 T cells previously infected or uninfected by HIV-1 followed by AAV amplification with wild-type adenovirus. Six rounds of biological selection were performed, including negative selection and diversification after round three. The H9 T cells were successfully infected with all three wild-type viruses (AAV, adenovirus, and HIV-1). Four AAV cap mutants best representing the small number of variants emerging after six rounds of selection were chosen for further study. These mutant capsids were used to package an AAV vector and subsequently used to infect H9 cells that were previously infected or uninfected by HIV-1. A quantitative polymerase chain reaction assay was performed to measure cell-associated AAV genomes. Two of the four cap mutants showed a significant increase in the amount of cell-associated genomes as compared to wild-type AAV2. This study shows that directed evolution can be performed successfully to select for mutants with improved tropism for a T cell line in the presence of HIV-1.

Capsid↗
PubMed2014

Engineering adeno-associated viruses for clinical gene therapy.

Clinical gene therapy has been increasingly successful owing both to an enhanced molecular understanding of human disease and to progressively improving gene delivery technologies. Among these technologies, delivery vectors based on adeno-associated viruses (AAVs) have emerged as safe and effective and, in one recent case, have led to regulatory approval. Although shortcomings in viral vector properties will render extension of such successes to many other human diseases challenging, new approaches to engineer and improve AAV vectors and their genetic cargo are increasingly helping to overcome these barriers.

Capsid↗
PubMed1996

Tobamovirus cross protection using a potexvirus vector.

Cross protection is the ability of one virus to prevent or delay infection by a related challenge virus. To examine this phenomena, a potato X potexvirus (PVX) vector (Chapman et al., 1992, Plant J. 2, 549) was used to systemically express the tobacco mosaic tobamovirus (TMV) coat protein (CP) open reading frame in Nicotiana benthamiana. PVX constructs induce mild mosaic symptoms in N. benthamiana, whereas TMV infection results in rapid systemic necrosis and plant death. Healthy plants or plants preinfected with the unmodified PVX vector succumbed to necrosis within 1 week of TMV challenge inoculation. However, plants preinfected with PVX vectors expressing the TMV CP or RNA coding sequence displayed a 1- to 2-week delay in the appearance of TMV-induced necrosis along with reduced accumulations of TMV. Symptom delay and reductions in the accumulation of TMV were more pronounced in plants protected with the vector expressing the TMV CP than with the vector expressing a nontranslatable CP sequence. Protection was overcome more quickly using a 10-fold higher concentration of challenge inoculum and was ineffective against TMV RNA or a TMV construct expressing a distantly related tobamovirus CP. These findings demonstrate that both RNA and protein are involved in this cross protection phenomenon, but that CP is the main contributor to protection. Taken together, these studies indicate that virus vectors can be used to simulate both cross protection and transgene-derived coat protein-mediated protection, thus providing a new method to further investigate the mechanisms behind each.

Capsid↗